Unmitigated early-life seizures are associated with life-long physical, cognitive, and behavioral impairments. Early and accurate diagnosis of infantile and childhood seizure disorders is a crucial first step in identifying effective treatment that can mitigate the impacts of seizures on the developing brain. Unfortunately, diagnosis and subtype classification of early-onset epilepsies is frequently delayed until long after the seizures have begun. Clinicians need to confidently differentiate Dravet syndrome (DS), Lennox-Gastaut syndrome (LGS), and tuberous sclerosis complex (TSC), as causes of seizure to form efficient strategies to treat these notoriously resistant conditions. Further, the diagnostic journey and disease management of children with epilepsy conditions is associated with significant quality of life (QoL) impacts on both the patient and family.
Please join expert faculty in this recorded CMEO webcast as they discuss topics including early diagnosis, patient/caregiver QoL, team-based care, the role of pharmaceutical cannabinoid (CBD) in treatment, and regulatory guidelines. Through this discussion learners will become acquainted with improved tactics to diagnose and treat early-life seizures.
This program is supported by an independent medical education grant from Jazz Pharmaceuticals, Inc.
Physicians, physician associates (PAs), nurse practitioners NPs), nurses, and pharmacists specializing pediatrics, neurology, primary care practicing in the U.S. and internationally.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.
Dr. Wirrell reports the following financial relationships:
Advisory Board: Biohaven and Eisai Inc.
Consultant: DSMB for Acadia Pharmaceuticals Inc.; Amicus Therapeutics, Inc.; GRIN Therapeutics; and Neurocrine Biosciences, Inc.
Grants: Dravet Syndrome Foundation
Research Support: (all payments made to Mayo) Marinus Pharmaceuticals, Inc.; UCB, Inc.; and Zogenix, Inc.
Ms. Dixon-Salazar reports the following financial relationships:
Advisory Board: Neurelis, Inc.
Dr. Reddy reports no financial relationships to disclose.
Dr. Strzelczyk reports the following financial relationships:
Advisory Board: Desitin Arzneimittel GmbH; Jazz Pharmaceuticals/GW Pharmaceuticals; UCB, Inc.; and Zogenix
Consultant: Angelini Pharma; Biocodex; Desitin Arzneimittel GmbH; Jazz Pharmaceuticals/GW Pharmaceuticals; Precisis GmbH; Takeda Pharmaceutical Company Limited; UNEEG medical; UCB, Inc.; and Zogenix
Speakers Bureau: Angelini Pharma; Desitin Arzneimittel GmbH; Eisai Inc.; Jazz Pharmaceuticals/GW Pharmaceuticals; UCB, Inc.; and Zogenix
Dr. Thomas reports the following financial relationships:
Advisory Board: Neurelis, Inc. and SK Life Science, Inc.
Consultant: Greenwich Biosciences, Inc. and SK Life Science, Inc.
Speakers Bureau: Eisai Inc.; Greenwich Biosciences, Inc.; LivaNova; and SK Life Science, Inc.
Disclosures were obtained from the CME Outfitters, LLC staff; no disclosures to report:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Call us at 877.CME.PROS (877.263.7767).